Objective To assess whether post-authorisation studies registered with the European Medicines Agency (EMA) adhere to legislation and recommendations to publicly post study protocols and results.
Nearly one in four U.S. households reports using a GLP-1 medication, and projections suggest that figure could rise to 35 percent by 2030. However, new research shows many users may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results